Current studentsExisting staffContact us
 

Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration

Simple item page
dc.contributor.authorWickremasinghe, S.
dc.contributor.authorMichalova, K.
dc.contributor.authorGilhotra, J.
dc.contributor.authorGuymer, R.
dc.contributor.authorHarper, C.
dc.contributor.authorWong, T.
dc.contributor.authorQureshi, S.
dc.date.issued2008
dc.description.abstractPurpose: Bevacizumab is an inhibitor of vascular endothelial growth factor widely used as an “off-label” treatment of neovascular age-related macular degeneration (AMD), despite the lack of clinical trial data on efficacy or safety of this drug. We describe acute intraocular inflammation after intravitreous injection of bevacizumab for the treatment of neovascular AMD. Design: A retrospective case series. Participants: Patients with neovascular AMD treated with intravitreous injection of bevacizumab from clinical practices in 2 states (Victoria and South Australia) in Australia. Methods: We retrospectively reviewed cases of acute intraocular inflammation after intravitreous injection of bevacizumab for the treatment of neovascular AMD. Main Outcome Measures: The detection and description of inflammation in a large cohort of patients. Results: There were 14 cases (11 women and 3 men), from a total of 1278 injections given. The mean age of patients was 83.7 years (range, 74–98). The majority had a prior injection of bevacizumab, with a mean number of injections of 2.7 (range, 1–6). Most patients presented within 24 hours of intravitreous injection, with rapid reduction in vision, but minimal discomfort. There were associated signs of ocular inflammation in the anterior and posterior segments of the eye. Visual acuity at presentation was substantially reduced compared with the preinjection acuity, although the vision rapidly improved with treatment over a period of 7–25 days toward preinjection visual acuity. Conclusions: Intravitreous injection of bevacizumab for the treatment of neovascular AMD may be associated with acute intraocular inflammation. Differentiation from infectious endophthalmitis is important for appropriate management of this condition.
dc.description.statementofresponsibilitySanjeewa S. Wickremasinghe, Kira Michalova, Jagjit Gilhotra, Robyn H. Guymer, C. Alex Harper, Tien Y. Wong and Salmaan Qureshi
dc.description.urihttp://www.elsevier.com/wps/find/journaldescription.cws_home/620418/description#description
dc.identifier.citationOphthalmology, 2008; 115(11):1911-1915
dc.identifier.doi10.1016/j.ophtha.2008.05.007
dc.identifier.issn0161-6420
dc.identifier.issn1549-4713
dc.identifier.urihttp://hdl.handle.net/2440/55557
dc.language.isoen
dc.publisherElsevier Science Inc
dc.source.urihttps://doi.org/10.1016/j.ophtha.2008.05.007
dc.subjectVitreous Body
dc.subjectHumans
dc.subjectEndophthalmitis
dc.subjectMacular Degeneration
dc.subjectChoroidal Neovascularization
dc.subjectAcute Disease
dc.subjectAngiogenesis Inhibitors
dc.subjectVascular Endothelial Growth Factor A
dc.subjectAntibodies, Monoclonal
dc.subjectInjections
dc.subjectRetrospective Studies
dc.subjectVisual Acuity
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectFemale
dc.subjectMale
dc.subjectAntibodies, Monoclonal, Humanized
dc.subjectBevacizumab
dc.titleAcute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Opthalmology & Visual Sciences publications